Despite this potential confounder, tumor cell content was previously evaluated and available for 579 cases within the 909 BC cohort36 and was not significantly associated to the rates of HER2 status false-negatives, false-positives, true-negatives, or true-positives in our material (Supplementary Fig. 3). The gene discussed is ERBB2; the disease is breast cancer.